Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Artemether + lumefantrine for uncomplicated falciparum malaria in Pakistan
ACTRN12617001025325Phase 4Completed
- Sponsor
- Ministry of National Health Services Regulations and Coordination
- Start
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of artemether and lumefantrine in Malaria, sponsored by Ministry of National Health Services Regulations and Coordination. Primary endpoints: PCR-corrected treatment failure rate, Adequate clinical and parasitological response and 1 more. Started Sep 2017; status: completed.
02
Drugs
artemetherlumefantrine
03
Conditions
Malaria
Beyond the preview
Go deeper on ACTRN12617001025325.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12617001025325.